mifepristone

Phase 3Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cushing's Disease

Conditions

Cushing's Disease

Trial Timeline

Aug 1, 2013 → —

NCT ID

NCT01925092

About mifepristone

mifepristone is a phase 3 stage product being developed by Corcept Therapeutics for Cushing's Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01925092. Target conditions include Cushing's Disease.

What happened to similar drugs?

2 of 9 similar drugs in Cushing's Disease were approved

Approved (2) Terminated (0) Active (7)

🔄pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3

🔄Pasireotide sub-cutaneousNovartisPhase 3

🔄osilodrostat + osilodrostat PlaceboNovartisPhase 3

🔄PasireotideNovartisPhase 3

✅Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved

✅Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved

🔄mifepristoneCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04588688	Phase 2	Terminated	May 5, 2021	Aug 1, 2021	Central Adrenal Insufficiency
NCT03258372	Phase 1	Completed	Aug 16, 2017	Nov 29, 2017	Healthy
NCT02642939	Phase 2	Terminated	Dec 1, 2015	Oct 15, 2020	Non-Small Cell Lung Cancer (NSCLC)
NCT01925092	Phase 3	Withdrawn	Aug 1, 2013	—	Cushing's Disease
NCT01371565	Phase 3	Completed	Nov 1, 2010	Sep 1, 2012	Cushing's Disease
NCT00936741	Phase 3	Completed	Jul 1, 2009	Sep 1, 2012	Cushing's Syndrome
NCT00569582	Phase 3	Completed	Dec 1, 2007	—	Cushing's Syndrome
NCT00128505	Phase 3	Completed	Aug 1, 2005	Nov 1, 2006	Major Depressive Disorder
NCT00208156	Phase 3	Completed	May 1, 2005	Nov 1, 2006	Depressive Disorder, Major
NCT00105105	Phase 2	Terminated	Apr 1, 2003	Nov 1, 2005	Alzheimer's Disease

Competing Products

18 competing products in Cushing's Disease

See all competitors

Product	Company	Stage	Hype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone	AstraZeneca	Phase 2	35
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg	Novartis	Phase 3	40
Pasireotide sub-cutaneous	Novartis	Phase 3	40
osilodrostat + osilodrostat Placebo	Novartis	Phase 3	40
Osilodrostat	Novartis	Phase 2	35
Pasireotide	Novartis	Phase 3	40
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin	Novartis	Approved	43
SOM230 s.c.	Novartis	Phase 2	35
Lu AG13909	Lundbeck	Phase 2	39
Osilodrostat	Recordati	Pre-clinical	23
Pasireotide + Cabergoline + Pasireotide LAR	Recordati	Approved	40
osilodrostat	Recordati	Phase 2	32
Osilodrostat	Recordati	Pre-clinical	27
mifepristone	Corcept Therapeutics	Phase 3	37
CORT125134	Corcept Therapeutics	Phase 2	32
Cushing's syndrome confirmation	Corcept Therapeutics	Pre-clinical	15
Mifepristone	Corcept Therapeutics	Phase 3	37
mifepristone	Corcept Therapeutics	Phase 3	37